Abstract | PURPOSE:
Samidorphan (3-carboxamido-4-hydroxy naltrexone) is a novel opioid receptor antagonist that is currently in clinical development. The oral dose pharmacokinetics, safety, and tolerability of samidorphan were evaluated in 2 double-blind, placebo-controlled, randomized studies in healthy adults. METHODS: The first study investigated single, ascending doses of 3.7 to 55.7 mg of samidorphan in 16 healthy adults; the second study evaluated multiple ascending doses of 10 or 20 mg of samidorphan administered for 7 days in 30 healthy adults. FINDINGS: Across the two studies, 39 of 46 subjects were male; 32 were white, 11 were black, and 3 were hispanic. Mean age was 34.9 years and mean weight was 84.2 kg. In both studies, samidorphan was rapidly absorbed, with a Tmax of 1 hour, and AUC increased with increasing dose. Samidorphan plasma levels declined in a monoexponential manner, with a half-life of ~7 to 9 hours. After multiple doses, steady state was approached by day 6 and achieved by day 7 after the 10-mg dose, but steady state was not reached for the 20-mg dose. Accumulation was low, with accumulation ratios <1.65. In both studies, samidorphan was generally well tolerated, with somnolence reported as the most common adverse event. IMPLICATIONS: In these single- and multiple-dose studies in healthy volunteers, samidorphan exhibited a pharmacokinetic profile consistent with once-daily dosing. ClinicalTrials.gov identifier: NCT00800319.
|
Authors | Ryan Turncliff, Lauren DiPetrillo, Bernard Silverman, Elliot Ehrich |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 37
Issue 2
Pg. 338-48
(Feb 01 2015)
ISSN: 1879-114X [Electronic] United States |
PMID | 25456560
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved. |
Chemical References |
- ALKS-33
- Morphinans
- Narcotic Antagonists
- Naltrexone
- 3-carboxamido-4-hydroxynaltrexone
|
Topics |
- Administration, Oral
- Adult
- Area Under Curve
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Dyssomnias
(chemically induced)
- Female
- Half-Life
- Healthy Volunteers
- Humans
- Male
- Middle Aged
- Morphinans
(administration & dosage, adverse effects, pharmacokinetics)
- Naltrexone
(administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics)
- Narcotic Antagonists
(administration & dosage, adverse effects, pharmacokinetics)
|